10x Science
10x Science is a YC Winter 2026 (W26) company. Based in San Francisco, CA, USA. Team of 3.
About 10x Science
Summary
10x Science builds an AI-native platform that automates protein characterization for drug developers. As AI-driven discovery floods pipelines with new therapeutic candidates, scientists face months of manual analysis to evaluate whether each candidate is viable before it can advance to clinical trials. 10x Science replaces that bottleneck, letting teams identify which candidates to advance and which to cut, earlier and with greater confidence.
Business model
B2B SaaS sold to enterprise pharma customers
Go-to-market
Drug developers at enterprise pharma companies are the primary buyers; the platform is sold directly to those organizations as a software solution for their protein characterization workflows.
From the Y Combinator listing
The AI-native platform for next-generation protein characterization.
10x Science develops frontier AI models with deep memory to redefine how scientists understand and engineer biology across the life sciences, starting with drug development. AI-powered drug discovery is flooding the pipeline with new candidates faster than ever. But before any of them can advance to the clinic, scientists must deeply characterize the protein therapeutic to understand whether it will work. Today, that process takes months of manual, error-prone analysis that cannot keep pace with discovery. Our AI-native platform automates it, giving drug developers the confidence to advance the right candidates and stop the wrong ones early. We have strong commercial traction with enterprise pharma customers. Our founding team built the field of next-generation protein characterization out of Carolyn Bertozzi's Nobel laureate lab at Stanford. Collectively, we have 18+ years of collective domain expertise, 47+ scientific publications, and a 2x YC Founder. We move at the highest velocity and are positioned to lead the next generation of modern AI development in the life sciences.
Facts
- B2B / B2B
- San Francisco, CA, USA
- 3
- Active
- Early
Founders (3)
- Andrew Reiter
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works